Xencor narrows annual loss 60% on earnings beat, strong cash position
Biotechnology company reports $610.8M cash runway extending through 2028 as FY2026 guidance projects $400-430M revenue
Xencor shares rose 1.4% on Thursday after the clinical-stage biopharmaceutical company reported fourth-quarter earnings that significantly exceeded analyst expectations, while demonstrating a dramatically improved financial trajectory compared to the previous year.
The Monrovia, California-based company posted a loss of 9 cents per share in the final quarter of 2025, far better than the 70-cent loss projected by Wall Street analysts, representing an 87.2% earnings beat, according to the company's quarterly results. Revenue of $28.2 million narrowly missed the $28.7 million consensus estimate, a 1.6% shortfall.
More significantly for long-term investors, Xencor's full-year 2025 loss narrowed 60% to $1.24 per share, down from a $3.58 loss in 2024, showing substantial progress in the company's path toward profitability. The company closed the year with a robust cash position of $610.8 million, providing a runway that extends through 2028.
"We made significant progress across our clinical programs in 2025, and we enter 2026 with multiple catalysts ahead," said Bassil Dahiyat, Xencor's chief executive officer, in the earnings announcement. "With our strong cash position, we are well-positioned to advance our pipeline programs and deliver on our strategic priorities."
Xencor issued guidance for fiscal year 2026, projecting total revenue between $400 million and $430 million. The company anticipates a significant portion will come from potential royalty revenue of $100-120 million from Alexion's Ultomiris through 2028. Ultomiris, an antibody therapy for certain rare diseases, incorporates Xencor's Xtend technology, which extends the half-life of therapeutic antibodies.
The company specializes in developing cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases. Its XmAb platform technology focuses on improving the therapeutic properties of antibodies, an approach that has attracted partnership interest from larger pharmaceutical companies.
Despite Thursday's modest gain, Xencor's shares have faced pressure in recent months. The stock closed at $11.98, well below its 52-week high of $18.69 but above its year-to-date low of $6.92. The shares remain 16% below their 50-day moving average of $14.26, though they trade above the 200-day moving average of $11.32.
Analyst sentiment remains strongly positive on the biotechnology company. Of 14 analysts covering the stock, 13 maintain buy or strong-buy ratings with a single hold, according to market data. The consensus price target stands at $28.83, implying significant upside from current levels and suggesting strong confidence in the company's pipeline and commercial potential.
Institutional ownership exceeds 115%, reflecting the company's relatively small market capitalization of $838 million and the high level of conviction among professional investors. Insider ownership is modest at 1.25%.
Xencor's progress in narrowing losses while maintaining a substantial cash cushion comes as investors in the biotechnology sector increasingly focus on companies with sustainable capital structures and clear pathways to profitability. The company's ability to beat earnings expectations while reducing its burn rate by 60% year-over-year suggests improved operational efficiency and capital allocation.
Looking ahead, investors will be watching for clinical trial updates from Xencor's pipeline programs, which could provide additional catalysts beyond the Ultomiris royalty stream. The company's guidance through 2028 provides visibility on cash flows, a critical consideration for investors in clinical-stage biotechnology companies that often require significant capital to advance potential therapies through development.